Skip to main content

Sarah Phyllis Young

Professor of Pediatrics
Pediatrics, Medical Genetics
Box 103856, Durham, NC 27710
801 Capitola Drive, Suite 6, Durham, NC 27713

Research Interests


Biomarkers for inborn errors of metabolism that support the diagnosis and treatment monitoring of patients with rare genetic disorders.
Development of clinical assays for the analysis of biomarkers of metabolic disorders.

Selected Grants


Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I

ResearchPrincipal Investigator · Awarded by Childrens Hospital of Orange County · 2023 - 2026

Biomarker studies in plasma from patients with Gaucher disease

ResearchCo Investigator · Awarded by Shire Human Genetics Therapies · 2018 - 2025

Liver-directed AAV gene therapy for PHKG2-Glycogen Storage Disease IX (GSD IX y2)

FellowshipMentor · Awarded by National Institutes of Health · 2021 - 2024

Evaluation of urinary Hex4 in Pompe and wild-type mice

ResearchPrincipal Investigator · Awarded by Aro Biotherapeutics · 2022 - 2023

Urinary Glc4 as a Marker of Glycogen Synthesis

ResearchPrincipal Investigator · Awarded by Maze Therapeutics · 2021 - 2022

Identifying Pathogenic Non-Coding Mutations in Rare Mendelian Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2022

Measurement of acylcarnitine, carnitine, and acetyl-L-carnitine levels in coded samples

ResearchPrincipal Investigator · Awarded by Rockefeller University · 2017 - 2021

Investigating Autophagy in GSD-Ia

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021

Pharmacodynamic study using rhaGLU in a Pompe mouse model. Nonclinical GAA-KO mouse study design proposal rhaGLU

ResearchCo-Principal Investigator · Awarded by Pharming Group N.V. · 2019 - 2021

GSD III Clinical Data Manuscript Preparation

ResearchInvestigator · Awarded by Ultragenyx Pharmaceutical · 2019 - 2021

Measurement of acylcarnitine, carnitine, and acetyl-L-carnitine levels in coded samples from subjects with depressive episodes

ResearchPrincipal Investigator · Awarded by Rockefeller University · 2015 - 2020

A Phase I Study of the Safety of AAV2/8 LSPhGAA in Late-onset Pompe Disease

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2017 - 2020

Potency Assays

ResearchInvestigator · Awarded by Actus Therapeutics · 2018 - 2019

Intraarticular Gene Therapy for Canine Mucopolysaccharidosis Type I Joint Disease

ResearchPrincipal Investigator · Awarded by Childrens Hospital of Orange County · 2017 - 2019

Gender and APOE genotype interact to alter immune regulated metabolism in AD

ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2019

Activity and Biodistribution of the AAV2/8-LSPhGAA in GAA-knockout mice

ResearchCo Investigator · Awarded by Actus Therapeutics · 2018 - 2018

Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia

ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2018

Analysis of a urinary glucose tetrasaccharide in a mouse model of Pompe disease

ResearchPrincipal Investigator · Awarded by Amicus Therapeutics Corporation · 2017 - 2018

Supplemental Funding for Phase 1/2 study of Clenbuterol for the Treatment of Pompe Disease

Clinical TrialCo Investigator · Awarded by Roivant Sciences, Inc. · 2015 - 2016

Phase 1/2 Study of Clenbuterol for the Treatment of Pompe Disease

Clinical TrialCo Investigator · Awarded by Food and Drug Administration · 2013 - 2016

Clinical Trial Planning in Pompe Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2014

Urinary F2-isoprostanes as a new biomarker for the risk of type 2 diabetes

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2013

Mechanisms for immune tolerance in Pompe Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2011

External Relationships


  • Association for Creatine Deficiencies
  • College of American Pathologists

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.